Anti-influenza therapies that target the host

New anti-influenza therapies that target the host instead of the virus have shown promise in laboratory tests and animal models, offering a potential solution to growing concerns over antiviral resistance. Researchers led by Kyoung-Oh Cho tested two novel drugs, AGM-380d, a dimer, and AGM-380t, a tetramer, that bind to a protein called nucleolin. This protein plays a crucial role in helping influenza viruses enter cells, replicate, and spread. By targeting nucleolin, these drugs disrupt the virus’s ability to function, effectively halting its life cycle without directly attacking the virus itself. The study, published in PNAS Nexus, demonstrated that both AGM-380d and AGM-380t were able to trap influenza viruses inside the nucleus of cultured cells, preventing them from replicating. This was observed in both pandemic and seasonal flu strains, indicating the broad applicability of the treatment. In addition to inhibiting replication, the drugs reduced lung viral load and minimized tissue damage in mice infected with influenza A. When combined with oseltamivir, commonly known as Tamiflu, the drugs ensured complete survival of all test animals, suggesting a synergistic effect between the new compounds and existing antivirals. Nucleolin is a multifunctional phosphoprotein primarily located in the nucleolus, a region of the cell nucleus involved in ribosome production. Many viruses, including influenza, exploit nucleolin to facilitate their entry into host cells and subsequent replication. By blocking this interaction, the new drugs prevent the virus from completing its life cycle. This strategy represents a shift away from traditional antiviral treatments, which can become ineffective due to rapid viral mutation and resistance development. The researchers emphasize that nucleolin-binding drugs could offer a more durable and effective approach to combating influenza. Unlike conventional antivirals, which must keep pace with evolving viral strains, host-targeted therapies may remain effective even as the virus mutates. This is because they attack a part of the host cell that is less likely to change, making them potentially more resilient to resistance. The findings come at a time when global public health officials are increasingly concerned about the limitations of current influenza treatments. Seasonal influenza causes hundreds of thousands of deaths annually, and the emergence of resistant strains threatens to undermine progress made in controlling the disease. The new drugs provide a potential breakthrough by addressing the root mechanism through which the virus interacts with the host, rather than merely suppressing symptoms or temporarily slowing replication. The research team, based at an undisclosed institution, has already begun exploring clinical applications of the drugs. While human trials are yet to commence, preliminary results suggest that the compounds could be developed into therapeutic options that complement or replace existing antiviral medications. The study highlights the importance of innovative approaches in virology and underscores the need for continued investment in research aimed at overcoming drug resistance. As the world continues to grapple with infectious diseases, such advancements represent a critical step forward in global health preparedness.